iBio's IBIO-610 shows 2.3% lower body weight versus vehicle in 28-week primate study
IBIO•iBio said its obesity candidate IBIO-610 produced 2.3% lower body weight versus vehicle in a 28-week primate study. The company also reported reduced body fat and sustained suppression of Activin E.
1. Primate study results
iBio announced preclinical results showing IBIO-610 reduced weight gain in obese monkeys while generally preserving lean mass. Results presented at ObesityWeek on November 15, 2026, also showed reduced body fat and sustained suppression of Activin E.
2. Amylin candidate
A separate amylin candidate reduced food intake in rats. iBio plans further preclinical studies in diet-induced obesity models and will present the findings at PEGS Europe on November 19, 2026, and the Amylin-Based Therapeutics Summit on December 2, 2026.




